Abstract:Perturbation of huntingtin (HTT)'s physiological function is one postulated pathogenic factor in Huntington's disease (HD). However, little is known how HTT is regulated in vivo. In a proteomic study, we isolated a novel ~40kDa protein as a strong binding partner of Drosophila HTT and demonstrated it was the functional ortholog of HAP40, an HTT associated protein shown recently to modulate HTT's conformation but with unclear physiological and pathologic roles. We showed that in both flies and human cells, HAP40 maintained conserved physical and functional interactions with HTT. Additionally, loss of HAP40 resulted in similar phenotypes as HTT knockout. More strikingly, HAP40 strongly affected HTT's stability, as depletion of HAP40 significantly reduced the levels of endogenous HTT protein while HAP40 overexpression markedly extended its half-life. Conversely, in the absence of HTT, the majority of HAP40 protein were degraded, likely through the proteasome. Further, the affinity between HTT and HAP40 was not significantly affected by polyglutamine expansion in HTT, and contrary to an early report, there were no abnormal accumulations of endogenous HAP40 protein in HD cells from mouse HD models or human patients. Lastly, when tested in Drosophila models of HD, HAP40 partially modulated the neurodegeneration induced by full-length mutant HTT while showed no apparent effect on the toxicity of mutant HTT exon 1 fragment. Together, our study uncovers a conserved mechanism governing the stability and in vivo functions of HTT and demonstrates that HAP40 is a central and positive regulator of endogenous HTT. Further, our results support that mutant HTT is toxic regardless of the presence of its partner HAP40, and implicate HAP40 as a potential modulator of HD pathogenesis through its multiplex effect on HTT's function, stability and the potency of mutant HTT's toxicity.

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis

Huntingtin Interacting Proteins and Pathological Implications

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Loss of Hap1 Selectively Promotes Striatal Degeneration in Huntington Disease Mice

Accumulation of N-terminal Mutant Huntingtin in Mouse and Monkey Models Implicated As a Pathogenic Mechanism in Huntington's Disease

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models

Impaired Α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking and Function by Mutant Huntingtin

A Huntingtin-Associated Protein Enriched in Brain with Implications for Pathology

N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking

Ubiquitin-Activating Enzyme Activity Contributes to Differential Accumulation of Mutant Huntingtin in Brain and Peripheral Tissues

Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice

Inhibitor-based modulation of huntingtin aggregation mechanisms reduces fibril toxicity

Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Regulation of intracellular HAP1 trafficking.

Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation.

Differential expression and roles of Huntingtin and Huntingtin-associated protein 1 in the mouse and primate brains

Huntingtin-associated Protein-1 is a Modifier of the Age-at-onset of Huntington's Disease.